|
1
|
Roder DM: The epidemiology of gastric
cancer. Gastric Cancer. 5:5–11. 2002. View Article : Google Scholar
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Li J, Yen C, Liaw D, et al: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li DM and Sun H: TEP1, encoded by a
candidate tumor suppressor locus, is a novel protein tyrosine
phosphatase regulated by transforming growth factor beta. Cancer
Res. 57:2124–2129. 1997.PubMed/NCBI
|
|
5
|
Steck PA, Pershouse MA, Jasser SA, et al:
Identification of a candidate tumour suppressor gene, MMAC1, at
chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/ MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goberdhan DC and Wilson C: PTEN: tumour
suppressor, multifunctional growth regulator and more. Hum Mol
Genet. 12:R239–R248. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stambolic V, Suzuki A, de la Pompa JL, et
al: Negative regulation of PKB/Akt-dependent cell survival by the
tumor suppressor PTEN. Cell. 95:29–39. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Besson A, Robbins SM and Yong VW:
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J
Biochem. 263:605–611. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Waite KA and Eng C: Protean PTEN: form and
function. Am J Hum Genet. 70:829–844. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang YH, Lee HS and Kim WH: Promoter
methylation and silencing of PTEN in gastric carcinoma. Lab Invest.
82:285–291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German).
|
|
13
|
Bignell GR, Greenman CD, Davies H, et al:
Signatures of mutation and selection in the cancer genome. Nature.
463:893–898. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carracedo A, Alimonti A and Pandolfi PP:
PTEN level in tumor suppression: how much is too little? Cancer
Res. 71:629–633. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hollander MC, Blumenthal GM and Dennis PA:
PTEN loss in the continuum of common cancers, rare syndromes and
mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Backman SA, Ghazarian D, So K, et al:
Early onset of neoplasia in the prostate and skin of mice with
tissue-specific deletion of Pten. Proc Natl Acad Sci USA.
101:1725–1730. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JI, Soria JC, Hassan KA, et al: Loss
of PTEN expression as a prognostic marker for tongue cancer. Arch
Otolaryngol Head Neck Surg. 127:1441–1445. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tachibana M, Shibakita M, Ohno S, et al:
Expression and prognostic significance of PTEN product protein in
patients with esophageal squamous cell carcinoma. Cancer.
94:1955–1960. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McMenamin ME, Soung P, Perera S, Kaplan I,
Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded
primary prostate cancer correlates with high Gleason score and
advanced stage. Cancer Res. 59:4291–4296. 1999.PubMed/NCBI
|
|
21
|
Depowski PL, Rosenthal SI and Ross JS:
Loss of expression of the PTEN gene protein product is associated
with poor outcome in breast cancer. Mod Pathol. 14:672–676. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sano T, Lin H, Chen X, et al: Differential
expression of MMAC/ PTEN in glioblastoma multiforme: relationship
to locali zation and prognosis. Cancer Res. 59:1820–1824.
1999.PubMed/NCBI
|
|
23
|
Zheng H, Takahashi H, Murai Y, et al: Low
expression of FHIT and PTEN correlates with malignancy of gastric
carcinomas: tissue-array findings. Appl Immunohistochem Mol
Morphol. 15:432–440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leslie NR and Foti M: Non-genomic loss of
PTEN function in cancer: not in my genes. Trends Pharmacol Sci.
32:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harima Y, Sawada S, Nagata K, Sougawa M,
Ostapenko V and Ohnishi T: Mutation of the PTEN gene in advanced
cervical cancer correlated with tumor progression and poor outcome
after radiotherapy. Int J Oncol. 18:493–497. 2001.PubMed/NCBI
|
|
26
|
Yoshimoto M, Cunha IW, Coudry RA, et al:
FISH analysis of 107 prostate cancers shows that PTEN genomic
deletion is associated with poor clinical outcome. Br J Cancer.
97:678–685. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deng H, Wu RL, Zhou HY, Huang X, Chen Y
and Liu LJ: Significance of Survivin and PTEN expression in full
lymph node-examined gastric cancer. World J Gastroenterol.
12:1013–1017. 2006.PubMed/NCBI
|
|
28
|
Bai Z, Ye Y, Chen D, et al: Homeoprotein
Cdx2 and nuclear PTEN expression profiles are related to gastric
cancer prognosis. APMIS. 115:1383–1390. 2007. View Article : Google Scholar : PubMed/NCBI
|
